Abstract:Background: Cancer immunotherapy has generated significant excitement, mainly as a result of the development of immune checkpoint inhibitors. The blockade of PD-1 or its ligand with antibodies has resulted in impressive clinical efficacy. However, a subset of patients does not respond to biologic therapeutics, and another subset suffers from severe immune-related adverse events in certain cases. The modulation of the immune system with small molecules might yield surprising benefits. Methods: CD8+ cells were obtained through a magnetic cell sorting system (MACS), and their capabilities for IFN-γ release and PD-1 expression were analyzed. The in vitro effects of drugs were studied in a coculture system of tumor cells and activated CD8+ cells. We further isolated the primary tumor cells in tumor-bearing mice treated with CAI, DMF, 1-MT or a combination (CAI and DMF/CAI and 1-MT) and analyzed the percentages of CD8+ T cells and PD-1+CD8+ T cells among TILs. The selective anti-tumor immune reactions of the two drug combinations were confirmed in a coculture system consisting of B16-OVA cells and OVA-specific CTLs derived from OT-1 transgenic mice. The anti-tumor effects of the single drugs or combined therapies were assessed according to their capability to slow tumor growth and extend the life span of tumor-bearing mice, and they were compared with the effects of PD-1 antibody. Results: CAI increased IFN-γ release from activated T cells, which might strengthen the anti-proliferative and anti-metastatic effects on cancer cells. However, CAI also stimulated IDO1-Kyn metabolic circuitry in the tumor microenvironment and facilitated tumor cell immune evasion. Combining CAI with 1-MT or DMF disrupted PD-1 expression and promoted IFN-γ production in CD8+ T cells, and it also increased T lymphocyte infiltration in the tumor microenvironment, inhibited tumor growth and prolonged the life spans of tumor-bearing mice. Conclusion: Inhibitors of the IDO1-Kyn-AhR pathway could abolish the negative effects of CAI on CD8+ T cells and result in complementary and beneficial anti-tumor immune effects. The combination of CAI with 1-MT or DMF greatly augmented the ability of CD8+ T cells to kill malignant cells and showed a strong anti-cancer capability that was superior to that of either of the single agents was is comparable with that of anti-PD-1 antibody. The combinations of small molecules utilized in this study may serve as valuable new immunotherapy strategies for cancer treatment.

Design of Calixarene‐Based ICD Inducer for Efficient Cancer Immunotherapy

Rational design of ICD-inducing nanoparticles for cancer immunotherapy

A Self-Reporting Fluorescent Salicylaldehyde-Chlorambucil Conjugate As a Type-II ICD Inducer for Cancer Vaccines

Multifunctional Nano‐Biomaterials for Cancer Therapy Via Inducing Enhanced Immunogenic Cell Death

Self‐Reporting Fluorescent Salicylaldehyde‐Chlorambucil Conjugate As A Type II ICD Inducer for Cancer Vaccine

Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy

Synergistic Reinforcing of Immunogenic Cell Death and Transforming Tumor‐Associated Macrophages Via a Multifunctional Cascade Bioreactor for Optimizing Cancer Immunotherapy

Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy

A Pair of Deep Red Phosphorescent Responsive Emissive Cyclometalated Iridium (III) Complexes as Carbonic Anhydrase Inhibitor and Effective Theranostic Photosensitizer

Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy

Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials

Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy

Reinforcing the Induction of Immunogenic Cell Death Via Artificial Engineered Cascade Bioreactor‐Enhanced Chemo‐Immunotherapy for Optimizing Cancer Immunotherapy

Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy

A Cascade-Targeted Enzyme-Instructed Peptide Self-Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death

Immunogenic cell death inducers for enhanced cancer immunotherapy

Local Drug Delivery Techniques for Triggering Immunogenic Cell Death

Development of Potent Antibody Drug Conjugates Against ICAM1+ Cancer Cells in Preclinical Models of Cholangiocarcinoma

PAMAM-Based Polymeric Immunogenic Cell Death Inducer To Potentiate Cancer Immunotherapy

A Supramolecular “Trident” for Cancer Immunotherapy